Subtype
Lung Squamous Cell Carcinoma
CI-CAN-00003121LSCC · LUSCExplore in graph →
37 active trials14 evidence items
- NCIt
- C3493
- OncoTree
- LUSC
- DOID
- 3907
- UMLS CUI
- C0149782
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003121LSCC · LUSCExplore in graph →
Clinical trials
141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03373760 | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | completed | Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 9, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT02920476 | TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | completed | Phase 2 | 4 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02417701 | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03574753 | Lung-MAP S1400K: c-MET Positive | completed | Phase 2 | 28 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 18, 2021 | clinicaltrials |
| NCT03377556 | Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 | 51 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 23, 2021 | clinicaltrials |
| NCT02785939 | Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 / Phase 3 | 53 | SWOG Cancer Research NetworkNETWORK | 1 | May 27, 2021 | clinicaltrials |
| NCT02965378 | Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 / Phase 3 | 43 | SWOG Cancer Research NetworkNETWORK | 2 | May 27, 2021 | clinicaltrials |
| NCT02785913 | Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | completed | Phase 2 | 31 | SWOG Cancer Research NetworkNETWORK | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01948141 | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | completed | Phase 2 | 6 | Roswell Park Cancer InstituteOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00387374 | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 0 | Jan 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials